News · 26 weeks79+57%
2026-03-012026-08-23
Mix3890d
- Insider18(47%)
- SEC Filings8(21%)
- Other5(13%)
- Leadership3(8%)
- Analyst2(5%)
- Earnings2(5%)
Latest news
25 items- INSIDERDirector Meister Keith A. sold $145,556,398 worth of shares (679,574 units at $214.19) (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERSVP, Strategy/Corp Development Wedel Christensen Jakob sold $197,840 worth of shares (1,033 units at $191.52), decreasing direct ownership by 7% to 14,023 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- SECSEC Form 8-K filed by Illumina Inc.8-K - ILLUMINA, INC. (0001110803) (Filer)
- SECIllumina Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - ILLUMINA, INC. (0001110803) (Filer)
- SECSEC Form 8-K filed by Illumina Inc.8-K - ILLUMINA, INC. (0001110803) (Filer)
- INSIDERSEC Form 3 filed by new insider Coletti Julie Ann3 - ILLUMINA, INC. (0001110803) (Issuer)
- SECSEC Form FWP filed by Illumina Inc.FWP - ILLUMINA, INC. (0001110803) (Subject)
- INSIDERChief Commercial Officer Sullivan Michael C was granted 4,503 shares (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- SECIllumina Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ILLUMINA, INC. (0001110803) (Filer)
- INSIDERDirector Meister Keith A. sold $148,159,897 worth of shares (741,127 units at $199.91) (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERChief Legal Officer Davies Scott M sold $123,000 worth of shares (615 units at $200.00), decreasing direct ownership by 3% to 20,338 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- SECSEC Form 10-Q filed by Illumina Inc.10-Q - ILLUMINA, INC. (0001110803) (Filer)
- SECIllumina Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ILLUMINA, INC. (0001110803) (Filer)
- PRIllumina Reports Financial Results for Second Quarter of Fiscal Year 2026SAN DIEGO, July 30, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2026. Second quarter 2026 resultsRevenue of $1.16 billion for Q2 2026, up 9.5% from Q2 2025 and up 8.1% excluding the impacts of currency, acquisitions, and China ("ROW1 organic revenue growth")GAAP operating margin of 21.1% and non-GAAP operating margin of 22.5%GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.31"Illumina delivered strong results during the second quarter. Momentum continued to build through the first half of 2026, as our technology is enabling clinical customers to expand sequencing-intensive
- INSIDERSEC Form 3 filed by new insider Sullivan Michael C3 - ILLUMINA, INC. (0001110803) (Issuer)
- PRIllumina expands Billion Cell Atlas program with new AI drug developersPartners will use unprecedented data scale to advance more precise medicines to approvalSAN DIEGO, July 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer Formation Bio. As leaders in AI-driven drug discovery, design, and development, alliance members will use the unprecedented scale of Illumina's genome-wide perturbation data as infrastructure for the next generation of therapeutics. "We are building the cell atlas to address key bottlenecks across the drug discovery and development continuum," said Rami Mehio, senior vice president and
- PRIllumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, July 30, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's we
- PRIllumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal OfficerNew leaders bring extensive leadership experience across life sciences, diagnostics, and medical technologySAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the appointment of Mike Sullivan as Chief Commercial Officer, effective July 20, 2026, and Julie Coletti as Chief Legal Officer, effective August 3, 2026. The appointments add experienced leaders to Illumina's Executive Leadership Team as the company continues advancing its strategy, serving customers, driving growth, and delivering on its mission to improve human health around the world."We are excited to welcome Mike and Julie to Illumina," said Jacob Thaysen, chief executive officer of Illumina. "Mik
- INSIDERDirector Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERDirector Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- ANALYSTBernstein resumed coverage on Illumina with a new price targetBernstein resumed coverage of Illumina with a rating of Mkt Perform and set a new price target of $185.00
- INSIDERChief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERDirector Skovronsky Daniel was granted 1,674 shares (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERSEC Form 3 filed by new insider Skovronsky Daniel3 - ILLUMINA, INC. (0001110803) (Issuer)
- SECIllumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - ILLUMINA, INC. (0001110803) (Filer)
ILMN FAQ
7 questionsWhat does Illumina Inc. do?
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic...Where does ILMN stock trade?
Illumina Inc. (ILMN) is listed on NASDAQ.What sector and industry is ILMN in?
Illumina Inc. operates in the Health Care sector, Medical Specialities industry.When did Illumina Inc. go public?
Illumina Inc. (ILMN) completed its IPO in 2000.What are analysts saying about ILMN?
Illumina Inc. has had 8 recent analyst actions on file. The most recent action was from Bernstein: Mkt Perform on 2026-06-26.What companies are similar to ILMN?
Notable peers in the same industry include TMO (Thermo Fisher Scientific Inc), QGEN (Qiagen N.V.), TXG (10x Genomics Inc.). Compare ILMN side-by-side with any of them on Quantisnow.How can I track ILMN on Quantisnow?
Quantisnow aggregates Illumina Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ILMN to receive live email and push alerts on every new disclosure.